Best Practice & Research Clinical Haematology
Volume 21, Issue 1 , Pages 61-66 , March 2008

Older adults: Should the paradigm shift from standard therapy?

  • Elihu H. Estey, MD (Professor of Medicine)

      Affiliations

    • Corresponding Author InformationTel.: +1 713 792 7305; Fax: +1 713 794 4298.

References 

  1. Beran M, Luthra R, Kantarjian H, et al. FLT3 mutation and response to intensive chemotherapy in young adult and elderly patients with normal karyotype. Leukemia Research. 2004;28:547–550
  2. Kantarjian H, O'Brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer. 2006;106:1090–1098
  3. Estey E, Smith TL, Keating MJ, et al. Prediction of survival during induction therapy in patients with newly diagnosed acute myeloblastic leukemia. Leukemia. 1989;3:257–263
  4. Anderson JE, Kopecky KJ, Willman CL, et al. Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. Blood. 2002;100:3869–3876
  5. Appelbaum FR, Kopecky KJ, Tallman MS, et al. The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations. British Journal of Haematology. 2006;135:165–173
  6. Rowe JM, Neuberg D, Friedenberg W, et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood. 2004;103:479–485
  7. Tsimberidou AM, Kantarjian HM, Keating MJ, et al. Prognostic significance of ß-2 microglobulin levels in acute myeloid leukemia: analysis of 1293 patients. Blood. 2006;108:240a;[abstract 802]
  8. Bataille R, Grenier J, Sany J. Beta-2-microglobulin in myeloma: optimal use for staging, prognosis, and treatment–a prospective study of 160 patients. Blood. 1984;63:468–476
  9. Giles FJ, Bekele BN, O'Brien S, et al. A prognostic model for survival in chronic lymphocytic leukaemia based on p53 expression. British Journal of Haematology. 2003;121:578–585
  10. Albitar M, Johnson M, Do KA, et al. Levels of soluble HLA-I and beta2 M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapy. Leukemia. 2007;21:480–488

PII: S1521-6926(07)00096-5

doi: 10.1016/j.beha.2007.11.006

Best Practice & Research Clinical Haematology
Volume 21, Issue 1 , Pages 61-66 , March 2008

Article Tools

* Image Usage & Resolution